Executive Management, Advisory Board & Consultants 2018-05-07T18:00:50+00:00

Executive Management

James R. Musick, Ph.DChief Executive Officer
Dr. Musick founded the Company in its present form and has served in various management capacities since joining the Company in 1988. He earned a Ph.D. degree in biological sciences with a specialty in neuroscience from Northwestern University and completed post-doctoral work at the University of Utah. His academic career included the position of Assistant Professor of Physiology at the University of Utah, School of Medicine.

He joined Vitro Diagnostics in 1988 and directed all operations involved in the establishment of a diagnostic product line that included about 30 different purified antigen products. His direct responsibilities included research & development, manufacturing, intellectual property development and maintenance, marketing and sales. He was also responsible for the development & initial commercialization of the fertility drug VITROPIN™ as well as the cell immortalization program of the Company. He is an inventor or co-inventor of all issued and pending patents owned by the Company.

In 2000, he orchestrated the successful spin-off of the diagnostic operating division allowing the Company to focus on development of the Core technology of cell immortalization, stem cell line generation while establishing and commercializing initial the stem cell products for use in research and clinical development.

Erik Van Horn, BSChEQuality Assurance Director
Erik has extensive experience in the technical and managerial background in biologic manufacturing operations. He served in various senior positions at Amgen, Inc. for 12 years including manufacturing, strategic planning and regulatory roles where he was a key liaison between Amgen and the FDA. He has specific expertise in mid and long-term planning and logistical design of small and large manufacturing operations in the drug industry. He has an extensive background in the FDA regulatory environment and directs establishment and certification of the Company’s Quality Management System to maintain the company’s GMP and FDA compliance.
John Evans, B. Comm., C.A.Chief Financial Officer
John R. Evans has over thirty years of extensive experience in finance, accounting, business development, licensing and patent prosecution along with executive level experience in mergers and acquisitions of both private and public companies. He joined Vitro BioPharma in March of 2017. Prior to that he was a Director, Managing member and CEO of a number of companies requiring executive level leadership and financial and legal management services. John served as co-founder and CEO of Convergent Communication, Inc. where he grew the company to $250M in revenues and raised over $400M in private and public funds to support the company’s growth. John was CFO of ICG Communications from 1991 to 1994 where he listed the company on the American Stock exchange, completed numerous acquisition transactions and raised over $500M in private and public financings. Mr. Evans was an Ernst and Young telecommunications finalist for Entrepreneur of the Year (1999) and received the Alts Association Most Innovative Business Strategy Award (1999). He served on the Colorado Governor’s Commission on Science and Technology (1998-2000). Mr. Evans was a Canadian Chartered Accountant (C. A.) (1981 -2013) and holds a Bachelor of Commerce (B. Comm.) degree in Accounting and Finance (1978) from McMaster University.
Tiana Tonrey, M.S.Chief Operating Officer
Tiana earned her BS degree from Colorado State University and M.S. from Colorado State University School of Veterinary Medicine and Biomedical Sciences. She previously studied the effects of curcumin as a chemotherapeutic agent in canine osteosarcomas. She has experience as a toxicologist, in drug-related & chemical exposure cases.

She began her work with Vitro Biopharma in late 2013 and has assisted in the development and expansion of new products. She has developed several product lines, established cGLP guidelines and written and finalized standard operating procedures.

Advisory Board

Ken Oleszek, M.D.Clinical/Medical Advisor
Dr. Ken Oleszek, M.D. is owner/medical director of Colorado Stem Cell Treatment Center. He has been involved in clinical stem cell therapy for over 5 years, specializing in autologous adipose-derived SVF (Stromal Vascular Fraction) therapies. This means obtaining stem cells from the patient’s own fatty tissue.

Dr. Oleszek, M.D. is affiliated with the Cell Surgical Network and the exciting ground breaking clinical research that may revolutionize the treatment of many medical diseases. He feels the accessibility of adipose tissue and the recent advances in extracting the stem cells from adipose tissue offers new and exciting potentials of stem cell treatment. At his Denver office, he focuses on studying stem cell treatments for degenerative orthopedic issues, such as knee arthritis, and degenerative systemic diseases.

Dr. Oleszek is a member of the Cell Surgical Network, International Federation for Adipose Therapeutics and Science (IFATS), Perinatal Stem Cell Society and International Society for Cellular Therapy (ISCT). He is a Fellow of The American Society of Lasers in Medicine and Surgery, and a member of The American College of Physicians, and the American Academy of Cosmetic Surgeons.

After attending University of Colorado Medical School, he completed internship and residency in Internal Medicine at The University of New Mexico. Dr. Oleszek was born in upstate New York and moved to Colorado in his school years. With his training in Internal Medicine and degenerative diseases and experience with adipose tissue, Dr. Oleszek is excited to bridge these two areas of medicine with Stem Cell Treatments.

While Medical Director at Sandhill Scientific Inc./Meditech International Inc., Dr. Oleszek was involved in the use of Low Level Laser Therapy as treatment for acute and chronic musculoskeletal diseases.

Duane Knight, CPAFinancial Advisor
Mr. Knight has more than twenty-five years experience in consulting, accounting and corporate finance. From 2009 to the present, Mr. Knight served as the Operational Chief Financial Officer of Neuromonics, Inc., a privately held Australian firm, that is one of the only firms to offer an FDA-approved treatment of tinnitus, an often debilitating condition with continual ringing in the ears without auditory input. He oversees operations, finance (including a $2-million fund raise), accounting, auditing interface, HR and administration, corporate governance and IT. From 2007 to 2009, he was a partner of Trinity Capital Services, LLC, a Denver, CO-based investment bank, where he headed up the life science practice, while directing FINRA compliance, numerous private placements into client firms and sell side M&A engagements. From 2002 to 2007 he was Chief Financial Officer and VP of Finance of Denver Biomedical, Inc., a medical device firm that developed a novel catheter for the treatment of excess fluid buildup in typically terminally ill cancer patients. During his tenure, his responsibilities included business development that yielded 25% CAGR and EBITA CAGR of 34%. He was also responsible for gaining coverage by private insurance (Aetna) and Medicare reimbursement. He led several significant transactions including exit of a venture partner, recapitalization with a private equity firm, debt refinancing and ultimately, sale of the company to Cardinal Health, Inc. He was retained by Cardinal Health, Inc. to complete post-acquisition finance and integration/transition activities. Prior to 2002, Mr. Knight established his own public accounting and consulting firm and performed finance operations for various public and private firms, and was a senior audit manager for Hein & Associates, LLP.

Mr. Knight provides assistant in the ongoing business development activities of the Company, especially as related to turn-around to profitability and the achievement of sustained earnings growth and other relevant financial activities.


John Smith III, M.D.CLIA Lab Director/Clinical Consultant
Dr. Smith is a Board Certified Clinical Pathologist in Anatomic, Clinical and Dermatopathology. He practiced medicine from 1989 to 2017 at Kaiser Permante in Denver Colorado serving various positions during his tenure there. He serves at the Clinical Director and Clinical Consultant of Vitro Biopharma’s ClIA-registered clinical reference laboratory
Margi Haas, MT(ASCP)CLIA Technical Supervisor/Consultant
Ms. Haas received a Bachelor of Science degree from Colorado State University and performed a Medical Technology Internship at the University of Medicine and Dentistry of New Jersy. She is an ASCP Certified Medical Technologist and a Registered Microbiologist. She has previously developed the original quality system for a national clinical reference laboratory. She has managed operations of clinical laboratories consisting of 2 to 45 employees overseeing testing at multiple sites in various departments. She also has experience as a human resource manager. She oversees the operations of Vitro Biopharma’s CLIA-registered clinical laboratory and serves at its Technical Supervisor and consultant.